# Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy

> **NCT07629817** · PHASE3 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 1044 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy
- **COMBINATION_PRODUCT:** Radiation with Concurrent Chemotherapy
- **PROCEDURE:** Radical Esophagectomy

## Key facts

- **NCT ID:** NCT07629817
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-16
- **Primary completion:** 2032-03-15
- **Final completion:** 2032-03-15
- **Target enrollment:** 1044 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629817, "Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07629817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*